Betta Pharmaceuticals Co., Ltd.

C4 Therapeutics Announces 2025 Milestones for Oncology-Focused Degrader Medicines

4 months ago

• C4 Therapeutics is set to advance clinical development of cemsidomide, with Phase 1 data expected in late 2025 for multiple myeloma and non-Hodgkin’s lymphoma. • CFT1946, targeting BRAF V600 mutations in solid tumors, is progressing through Phase 1, with data readouts anticipated in the second half of 2025. • Phase 1 data from CFT8919, aimed at EGFR L858R-mutated non-small cell lung cancer, will inform future development plans outside of China. • C4 Therapeutics' cash runway is projected to fund operations into 2027, supporting ongoing research and clinical programs.

EyePoint's DURAVYU Shows Promise in Wet AMD and DME Trials, Anticipates Key Milestones in 2025

4 months ago

• EyePoint Pharmaceuticals' DURAVYU Phase 3 trials for wet AMD are progressing faster than expected, with the LUGANO trial one-third enrolled and LUCIA ahead of schedule. • Full data from the Phase 2 VERONA trial of DURAVYU in diabetic macular edema (DME) is anticipated in the first quarter of 2025. • EyePoint has appointed retina specialist Dr. Reginald J. Sanders to its Board and anticipates topline DURAVYU Phase 3 wet AMD data in 2026. • With approximately $370 million in cash, EyePoint's financial runway extends into 2027, supporting DURAVYU's clinical development and potential regulatory submissions.

C4 Therapeutics Stock Hits 52-Week Low Amid Market Volatility

5 months ago

C4 Therapeutics Inc. (CCCC) has seen its stock price drop to a 52-week low of $3.77, reflecting a 28.32% decrease year-to-date. Despite the downturn, the company maintains a strong liquidity position and has reported promising developments in its cancer drug trials and strategic appointments.

EyePoint's DURAVYU Enters Phase 3 Trial for Wet AMD with First Patient Dosed in LUCIA Study

6 months ago

• EyePoint Pharmaceuticals has dosed the first patient in the LUCIA trial, a Phase 3 study evaluating DURAVYU for wet age-related macular degeneration (AMD). • DURAVYU, a sustained-release therapy delivering vorolanib, aims to reduce the treatment burden associated with frequent intravitreal injections. • The LUCIA trial, along with the LUGANO trial, will assess the efficacy, safety, and dosing flexibility of DURAVYU with re-dosing every six months. • Topline data from the Phase 3 program is expected in 2026, potentially offering a new treatment paradigm for wet AMD patients.

Merus' Petosemtamab and Mersana's Emi-Le Show Promise in Cancer Treatment

6 months ago

• Merus' petosemtamab demonstrates a 36% overall response rate in recurrent/metastatic head and neck squamous cell carcinoma, with median overall survival of 11.4 months. • Mersana Therapeutics' Emi-Le receives Fast Track designation for HER2-negative breast cancer, showing promising monotherapy activity in multiple tumors. • Petosemtamab's clinical trials are ongoing, including phase 3 studies in HNSCC and expanded evaluation in metastatic colorectal cancer, with data updates planned for 2025.

Ensartinib Approved by FDA for First-Line ALK-Positive Non-Small Cell Lung Cancer

6 months ago

• The FDA has approved ensartinib (Ensacove) for first-line treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). • Ensartinib demonstrated statistically significant improvement in progression-free survival compared to crizotinib in the eXALT3 trial. • Common adverse reactions to ensartinib include rash, musculoskeletal pain, constipation, cough, pruritus, nausea, edema, pyrexia, and fatigue. • The recommended dose of ensartinib is 225 mg orally once daily until disease progression or unacceptable toxicity.